NasdaqCM:MOTS

Stock Analysis Report

Executive Summary

Motus GI Holdings, Inc. operates as a medical technology company to enhance the endoscopy outcomes in the United States and Israel.

Snowflake

Fundamentals

High growth potential with mediocre balance sheet.

Risks

  • Motus GI Holdings has significant price volatility in the past 3 months.

Share Price & News

How has Motus GI Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.5%

NasdaqCM:MOTS

-1.2%

US Medical Equipment

1.2%

US Market


1 Year Return

-50.6%

NasdaqCM:MOTS

8.7%

US Medical Equipment

1.7%

US Market

MOTS underperformed the Medical Equipment industry which returned 8.7% over the past year.

MOTS underperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

MOTSIndustryMarket
7 Day1.5%-1.2%1.2%
30 Day1.9%1.4%4.9%
90 Day-29.5%4.8%3.7%
1 Year-50.6%-50.6%9.6%8.7%3.9%1.7%
3 Yearn/a70.8%65.5%47.2%37.7%
5 Yearn/a130.4%104.1%60.0%42.4%

Price Volatility Vs. Market

How volatile is Motus GI Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Motus GI Holdings undervalued based on future cash flows and its price relative to the stock market?

7.24x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Motus GI Holdings to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Motus GI Holdings to establish if it is available at substantial discount.


Price Based on Earnings

Motus GI Holdings is loss making, we can't compare its value to the US Medical Equipment industry average.

Motus GI Holdings is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Motus GI Holdings, we can't assess if its growth is good value.


Price Based on Value of Assets

Motus GI Holdings is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Motus GI Holdings expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

50.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Motus GI Holdings's revenue is expected to grow significantly at over 20% yearly.

Motus GI Holdings's earnings are expected to grow significantly at over 20% yearly.

Motus GI Holdings's revenue growth is expected to exceed the United States of America market average.

Motus GI Holdings's earnings growth is expected to exceed the United States of America market average.

Motus GI Holdings's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Motus GI Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Motus GI Holdings performed over the past 5 years?

-37.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Motus GI Holdings does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Motus GI Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Motus GI Holdings's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Motus GI Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Motus GI Holdings has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Motus GI Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Motus GI Holdings's financial position?


Financial Position Analysis

Motus GI Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Motus GI Holdings's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Motus GI Holdings's level of debt (0%) compared to net worth is satisfactory (less than 40%).

Unable to establish if Motus GI Holdings's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 1.0773511028595E+17x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Motus GI Holdings has less than a year of cash runway based on current free cash flow.

Motus GI Holdings has less than a year of cash runway if free cash flow continues to grow at historical rates of 39.8% each year.


Next Steps

Dividend

What is Motus GI Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Motus GI Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Motus GI Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Motus GI Holdings has not reported any payouts.

Unable to verify if Motus GI Holdings's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Motus GI Holdings has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Motus GI Holdings's salary, the management and board of directors tenure and is there insider trading?

1.0yrs

Average management tenure


CEO

Tim Moran (47yo)

0.9yrs

Tenure

US$2,765,440

Compensation

Mr. Timothy P. Moran, also known as Tim, has been the Chief Executive Officer and a Director of Motus GI Holdings Inc. since October 1, 2018. He served as President of the Americas at ConvaTec Group Plc si ...


CEO Compensation Analysis

Tim's remuneration is higher than average for companies of similar size in United States of America.

Insufficient data for Tim to compare compensation growth.


Management Age and Tenure

1.0yrs

Average Tenure

48yo

Average Age

The average tenure for the Motus GI Holdings management team is less than 2 years, this suggests a new team.


Board Age and Tenure

2.8yrs

Average Tenure

47yo

Average Age

The average tenure for the Motus GI Holdings board of directors is less than 3 years, this suggests a new board.


Insider Trading

More shares have been bought than sold by Motus GI Holdings individual insiders in the past 3 months.


Recent Insider Transactions

BuyUS$3,000,00001 Jul 19
Perceptive Advisors LLC
EntityCompany
Shares1,000,000
Max PriceUS$3.00
BuyUS$89,94801 Jul 19
The Feinberg Family Foundation, Endowment Arm
EntityCompany
Shares30,000
Max PriceUS$3.00
BuyUS$3,005,55101 Jul 19
Oracle Investment Management, Inc.
EntityCompany
Shares1,001,666
Max PriceUS$3.02
BuyUS$24,99901 Jul 19
Gary Pruden
EntityIndividual
Shares8,333
Max PriceUS$3.00
BuyUS$3,00001 Jul 19
Mark Pomeranz
EntityIndividual
Role
Member of the Board of Directors
President
Shares1,000
Max PriceUS$3.00
BuyUS$9,99901 Jul 19
Timothy Moran
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares3,333
Max PriceUS$3.00
BuyUS$24,99901 Jul 19
Jacobs Investment Company, LLC
EntityCompany
Shares8,333
Max PriceUS$3.00
BuyUS$30,00001 Jul 19
David Hochman
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares10,000
Max PriceUS$3.00
BuyUS$16,90024 May 19
Timothy Moran
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares5,000
Max PriceUS$3.38
BuyUS$1,130,00018 Jan 19
Perceptive Advisors LLC
EntityCompany
Shares410,000
Max PriceUS$5.00
BuyUS$6,75026 Dec 18
Mark Pomeranz
EntityIndividual
Role
Member of the Board of Directors
President
Shares2,500
Max PriceUS$2.70
BuyUS$54,00026 Dec 18
David Hochman
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares20,000
Max PriceUS$2.70
BuyUS$2,70026 Dec 18
Andrew Taylor
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares1,000
Max PriceUS$2.70
BuyUS$27,00026 Dec 18
Timothy Moran
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares10,000
Max PriceUS$2.70
BuyUS$27,00026 Dec 18
Jacobs Investment Company, LLC
EntityCompany
Shares10,000
Max PriceUS$2.70
BuyUS$24,70828 Nov 18
Jacobs Investment Company, LLC
EntityCompany
Shares7,100
Max PriceUS$3.48
BuyUS$52,35021 Nov 18
David Hochman
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares15,000
Max PriceUS$3.49
BuyUS$52,20021 Nov 18
Timothy Moran
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares15,000
Max PriceUS$3.48

Ownership Breakdown


Management Team

  • Mark Pomeranz (58yo)

    President

    • Tenure: 0yrs
    • Compensation: US$501.96k
  • Andrew Taylor (48yo)

    Chief Financial Officer

    • Tenure: 2.1yrs
    • Compensation: US$356.54k
  • Tim Moran (47yo)

    CEO & Director

    • Tenure: 0.9yrs
    • Compensation: US$2.77m
  • Steven Bosrock

    Vice President of Global Marketing & Strategy

    • Tenure: 0.3yrs

Board Members

  • Shervin Korangy (43yo)

    Director

    • Tenure: 2.5yrs
    • Compensation: US$36.00k
  • Sam Nussbaum (70yo)

    Director

    • Tenure: 2.8yrs
    • Compensation: US$26.00k
  • David Hochman (44yo)

    Chairman of the Board

    • Tenure: 2.8yrs
    • Compensation: US$68.00k
  • Steven Edmundowicz

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Gary Jacobs (62yo)

    Director

    • Tenure: 2.8yrs
    • Compensation: US$26.75k
  • Mark Pomeranz (58yo)

    President

    • Tenure: 0yrs
    • Compensation: US$501.96k
  • Darren Sherman (47yo)

    Director

    • Tenure: 2.8yrs
    • Compensation: US$32.00k
  • Ian Gralnek

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Brian Jacobson

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Tim Moran (47yo)

    CEO & Director

    • Tenure: 0.9yrs
    • Compensation: US$2.77m

Company Information

Motus GI Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Motus GI Holdings, Inc.
  • Ticker: MOTS
  • Exchange: NasdaqCM
  • Founded: 2016
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$78.531m
  • Shares outstanding: 28.77m
  • Website: https://www.motusgi.com

Number of Employees


Location

  • Motus GI Holdings, Inc.
  • 1301 East Broward Boulevard
  • 3rd Floor, Suite 310
  • Fort Lauderdale
  • Florida
  • 33301
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MOTSNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDFeb 2018

Biography

Motus GI Holdings, Inc. operates as a medical technology company to enhance the endoscopy outcomes in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/15 00:34
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.